Abstract 1404P
Background
Combination of anti-PD1 inhibitor with chemoradiotherapy (CRT) has been shown to improve the survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC). This study specifically aims to identify circulating cytokines as biomarkers for predicting treatment response, survival, and immune-related toxicities.
Methods
Patients with locally advanced ESCC from two phase II clinical trials (EC-CRT-001 and NEOCRTEC1901) were pooled for analysis. All patients received CRT in combination with toripalimab, an anti-PD1 inhibitor. We longitudinally profiled 19 cytokines in the plasma before (pre), during, and after (post) CRT. The associations between cytokine levels and treatment response or immune-related toxicity were examined using the Wilcoxon test. Their correlations with overall survival (OS) and progression-free survival (PFS) were assessed through univariate and multivariate Cox analyses.
Results
A total of 81 patients were included, and 243 plasma samples were analyzed. Multivariate analyses indicated that pre-treatment levels of IL-8 and post-treatment levels of Granzyme B were independent prognostic markers for OS (p<0.05). Post-CRT levels of IL-10 were identified as independent prognostic markers for PFS (p<0.05). Subgroup analyses revealed correlations between pre- and during-CRT levels of IL-8, and post-CRT levels of IL-13 and IL-10 with a complete clinical response in the EC-CRT-001 group. Additionally, pre-CRT IL-8 and post-CRT CCL5 levels were associated with immune-related toxicities.
Conclusions
Circulating cytokines, particularly IL-8, serve as significant biomarkers for predicting response, survival, and immune-related toxicities in locally advanced ESCC patients undergoing combined chemoradiotherapy and toripalimab treatment.
Clinical trial identification
NCT04005170; NCT04006041.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
972P - Efficacy and safety of lenvatinib vs sorafenib in hepatocellular carcinoma: A multi-center real-world study from the LINK Research Network
Presenter: Jung Yong Hong
Session: Poster session 17
973P - Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 17
977P - Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: A multicenter cohort study
Presenter: Yi Chen
Session: Poster session 17
978P - Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, single center, phase Ⅱ clinical study
Presenter: Jinpeng Li
Session: Poster session 17
979P - Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial)
Presenter: Oliver Waidmann
Session: Poster session 17